The Numbers
Cauldron Ferm, a biomanufacturing startup based in Orange, NSW, closed a $13.25M Series A2 led by Main Sequence Ventures. Existing backers Horizons Ventures, SOSV, and NGS Super followed. Total raised: $19.5M across two Series A rounds since 2022.
The company operates a 30,000-litre demonstration facility in Orange (3.5 hours west of Sydney) and plans a full-scale factory in regional Australia, with Queensland government funding for a Mackay facility.
What They Do
Cauldron positions itself as APAC's largest end-to-end contract manufacturer for precision fermentation. They use proprietary hyper-fermentation tech to produce proteins (dairy, egg, spider silk) via microbes. The pitch: 5x productivity over batch methods, 55% less electricity, 20% less water.
They hold Australia's first OGTR approval for 10,000L-scale production. Clients are global precision fermentation firms looking to de-risk commercialisation.
The Sales Angle
Here's what's missing: no public data on sales team structure, headcount, CRO, VP Sales, or recent hires. No revenue disclosed. This is standard for early-stage contract manufacturing, but it signals limited near-term opportunities for B2B sales roles.
For biotech sales professionals tracking Series A hiring patterns: Cauldron is focused on operational scale-up (retrofitting facilities, deploying tech at partner sites), not go-to-market expansion. If they build a sales org, expect contract manufacturing AEs targeting precision fermentation clients, likely enterprise deals with long cycles.
Regional Reality
Orange-based with a planned Mackay facility. Regional biotech means fewer sales roles than Sydney or Melbourne hubs, but potential for technical account management as capacity scales. Watch for client partnerships that might require ANZ-based support roles.
CEO Michele Stansfield and CFO David Kestenbaum lead the team. Named Startup Daily Best Regional Startup 2025 and Fast Company World's Most Innovative 2026.